Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy

Inclusion Criteria: * Age range of 18 to 75 years old (including boundary values); * Conform to the diagnosis of type 2 diabetes and diabetes retinopathy. diabetes retinopathy is classified as NPDR and mild and moderate patients; * Patients with the best corrected visual acuity (BCVA) of the target eye is ≥ 34 points (ETDRS visual acuity chart, visual acuity equivalent to a score of 20/200, decimal 0.1); * Patients who meet the syndrome differentiation criteria of Yin deficiency, internal heat, and eye meridian stasis in traditional Chinese medicine; * During the screening period, glycated hemoglobin (HbA1c) should be ≤ 8.5%; * Agree to participate in this clinical study and voluntarily sign the informed consent form. Exclusion Criteria: * Patients with no light perception in one eye; * Patients with macular edema who require anti Vascular Endothelial Growth Factor(VEGF) treatment; * People with other eye diseases, such as retinal artery or vein occlusion, non diabetes retinopathy, retinal detachment, uveitis, glaucoma, corneal ulcer, cataract affecting fundus examination, optic neuropathy and high myopia with fundus changes; * Patients with acute complications of diabetes (such as diabetes ketoacidosis, hyperglycemia hyperosmolality syndrome, diabetes lactic acidosis, etc.) within one year before the screening period; * People with other eye related complications of diabetes, such as iris neovascularization, angle neovascularization, and retinal neovascularization; * acup…